title: Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma.
abstract: Kaposi sarcoma (KS) is a human herpesvirus-8-associated lymphoangioproliferative neoplasm. Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monoclonal anti-IL-6 receptor antibody approved for rheumatoid arthritis (RA) treatment, was effective not only in inducing RA remission but was also safe for KS.
authors.affiliation: Division of Rheumatology, Istituto Gaetano Pini, Department of Clinical Sciences and Community Health, University of Milano, Piazza Cardinal Ferrari 1, 20122, Milan, Italy, francesca.ingegnoli@unimi.it.
authors.forename: Francesca
authors.initials: F
authors.lastname: Ingegnoli
authors.forename: Athanasia
authors.initials: A
authors.lastname: Tourlaki
authors.forename: Roberta
authors.initials: R
authors.lastname: Gualtierotti
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007049:Iatrogenic Disease; D008297:Male; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors / Q000276:immunology; D012074:Remission Induction / Q000379:methods; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D019947:Receptors, Interleukin-6; C502936:tocilizumab